Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$9.88 USD
-0.66 (-6.22%)
Updated Oct 17, 2025 04:00 PM ET
After-Market: $9.94 +0.06 (0.61%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MRSN 9.88 -0.66(-6.22%)
Will MRSN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MRSN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRSN
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
MRSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
Other News for MRSN
Is MRSN poised for a decline? 200 Day Moving Average Resistance shows up after crashing 6.22%
200 Day Moving Average Resistance appears for MRSN after 0.05% move
Is MRSN likely to continue higher? Pocket Pivot shows up after advancing 2.23%
Upper Bollinger Band Walk appears for MRSN after 3.94% move
Is MRSN poised for gains? New Uptrend shows up after rallying 7.25%